Ernexa Therapeutics Inc.
ERNANASDAQHealthcare● Active
$7.39
$-0.50(-6.34%)
Market Cap$2321376
P/E Ratio—
52W High$71.5
52W Low$3.18
Ernexa Therapeutics Inc. (ERNA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ERNA · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$6.95
Est. -$1.95 · -256.4%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS
ERNA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$3.30 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 11, 2026 | -$1.95 | -$6.95 | -256.4% | — | — | — |
| — Q1 FY2026 | Mar 13, 2026 | — | -$0.25 | — | — | — | — |
| ▲ Q4 FY2025 | Nov 7, 2025 | -$33.00 | -$0.15 | +99.5% | — | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$39.00 | -$0.61 | +98.4% | — | — | — |
| ▲ Q2 FY2025 | May 7, 2025 | -$48.00 | -$2.25 | +95.3% | — | — | — |
| ▼ Q1 FY2025 | Mar 13, 2025 | -$37.50 | -$48.00 | -28.0% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.24 | -$0.74 | -207.3% | $0.00B | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$3.30
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
-$6.95
EPS Est.
-$1.95
EPS Surpr.
-256.4%
Revenue
—
Q1 FY2026
Mar 13, 2026
EPS Actual
-$0.25
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 7, 2025Beat
EPS Actual
-$0.15
EPS Est.
-$33.00
EPS Surpr.
+99.5%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.61
EPS Est.
-$39.00
EPS Surpr.
+98.4%
Revenue
—
Q2 FY2025
May 7, 2025Beat
EPS Actual
-$2.25
EPS Est.
-$48.00
EPS Surpr.
+95.3%
Revenue
—
Q1 FY2025
Mar 13, 2025Miss
EPS Actual
-$48.00
EPS Est.
-$37.50
EPS Surpr.
-28.0%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.74
EPS Est.
-$0.24
EPS Surpr.
-207.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $-2.89 | $-2.89 | $-2.89 | 1 |
| Q2 FY2028 | $-2.40 | $-2.40 | $-2.40 | 1 |
| Q1 FY2028 | $-2.11 | $-2.11 | $-2.11 | 1 |
| Q4 FY2027 | $-1.95 | $-1.95 | $-1.95 | 1 |
| Q3 FY2027 | $-900.00 | $-900.00 | $-900.00 | 1 |
| Q2 FY2027 | $-825.00 | $-825.00 | $-825.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -256.4% | $7.53 | $7.21 | -4.25% |
| — Q1 FY2026 | Mar 13, 2026 | — | $7.73 | $8.10 | +4.79% |
| ▲ Q4 FY2025 | Nov 7, 2025 | +99.5% | $42.25 | $43.75 | +3.55% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +98.4% | $42.25 | $40.75 | -3.55% |
| ▲ Q2 FY2025 | May 7, 2025 | +95.3% | $78.00 | $77.75 | -0.32% |
| ▼ Q1 FY2025 | Mar 13, 2025 | -28.0% | $97.50 | $95.75 | -1.79% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -207.3% | $423.75 | $405.00 | -4.42% |
| — Q3 FY2024 | Aug 13, 2024 | — | $697.50 | $675.00 | -3.23% |
Q2 FY2026-4.25%
Report Date
May 11, 2026
EPS Beat/Miss
-256.4%
Price Before
$7.53
Price After
$7.21
Q1 FY2026+4.79%
Report Date
Mar 13, 2026
EPS Beat/Miss
—
Price Before
$7.73
Price After
$8.10
Q4 FY2025+3.55%
Report Date
Nov 7, 2025
EPS Beat/Miss
+99.5%
Price Before
$42.25
Price After
$43.75
Q3 FY2025-3.55%
Report Date
Aug 13, 2025
EPS Beat/Miss
+98.4%
Price Before
$42.25
Price After
$40.75
Q2 FY2025-0.32%
Report Date
May 7, 2025
EPS Beat/Miss
+95.3%
Price Before
$78.00
Price After
$77.75
Q1 FY2025-1.79%
Report Date
Mar 13, 2025
EPS Beat/Miss
-28.0%
Price Before
$97.50
Price After
$95.75
Q4 FY2024-4.42%
Report Date
Nov 12, 2024
EPS Beat/Miss
-207.3%
Price Before
$423.75
Price After
$405.00
Q3 FY2024-3.23%
Report Date
Aug 13, 2024
EPS Beat/Miss
—
Price Before
$697.50
Price After
$675.00
Avg Beat Reaction-0.11%
Avg Miss Reaction-3.49%
Beat Rate3 / 8 quarters
Largest Move+4.79% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ERNA ends December
Ernexa Therapeutics Inc. (ERNA) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-6.95 — missing the analyst consensus of $-1.95 by -256.4%. The next ERNA earnings date is expected around September 1, 2026.
Each quarter, investors track ERNA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ERNA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ERNA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ERNA earnings · 5 questionsErnexa Therapeutics Inc.'s next earnings report is expected around September 1, 2026. ERNA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ERNA historically reports after market close (AMC).
ERNA earnings datewhen is ERNA earningsERNA next earnings datewhen does ERNA report earningsERNA earnings calendar
▸ Source: FMP · Ernexa Therapeutics Inc. SEC filings · US GAAP · Ernexa Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026